"The Overall Survival (OS) data from the SIRFLOX study is required to be combined with the FOXFIRE and FOXFIRE Global studies to provide sufficient statistical power in over 1,000 patients globally to detect a clinical significant difference in OS between the SIR-Spheres microspheres and control arms. Analysis of OS from the SIRFLOX study cannot be progressed at this time for reasons of (a) bias and (b) statistical power for these studies. Overall OS data is anticipated during 1H CY17."
With a p = 0.428 for OS of 10.7 mths versus 10.2, i read the above as a positive and that there's more to unravel. Still a long way off though.
- Forums
- ASX - By Stock
- SRX
- Ann: SIRFLOX ASCO Abstract Released
Ann: SIRFLOX ASCO Abstract Released, page-17
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)